More specifically, a comprehensive study conducted to understand the importance of transglutaminases in human cancers revealed that high TG2 levels in pancreatic cancer are associated with worse patient survival, resistance to gemcitabine, and an increase in macrophage recruitment due to the release of the chemokine CCL2 by cancer cells [111]; see Figure 8. The gene discussed is CCL2; the disease is cancer.